companiesCompany
Interius BioTherapeutics
Penn spin-out that dosed the first patient ever with a durable in vivo CAR gene therapy (INT2104, CD20) in the INVISE trial.
INT2104 is an engineered lentiviral vector that generates CAR-T and CAR-NK cells against CD20 after a single IV infusion, without lymphodepletion. Phase 1 INVISE in relapsed/refractory B-cell malignancies started in Australia (2024-25); preclinical large-animal data showed B-cell depletion without CRS or neurotoxicity.